Results from the Children's Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma
- PMID: 37969125
- PMCID: PMC10644028
- DOI: 10.21037/tp-23-388
Results from the Children's Oncology Group phase III trial of a monoclonal antibody against the insulin-like growth factor-1 receptor in patients with newly diagnosed metastatic Ewing sarcoma
Keywords: Metastatic Ewing sarcoma; clinical trial; ganitumab; insulin-like growth factor-1 receptor (IGF-1R).
Conflict of interest statement
Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tp.amegroups.com/article/view/10.21037/tp-23-388/coif). The author has no conflicts of interest to declare.
Comment on
-
Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group.J Clin Oncol. 2023 Apr 10;41(11):2098-2107. doi: 10.1200/JCO.22.01815. Epub 2023 Jan 20. J Clin Oncol. 2023. PMID: 36669140 Free PMC article. Clinical Trial.
References
-
- Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-6. 10.1200/JCO.2004.01.041 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources